Modified-release Hydrocortisone Outcomes in Congenital Adrenal Hyperplasia
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows adults with a genetic condition called congenital adrenal hyperplasia (CAH) who are switching to a new form of the steroid medication hydrocortisone. Researchers will track how well this modified-release version—which releases medication slowly over time—works for managing their condition in real-world practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a genetic diagnosis of 21-hydroxylase deficiency congenital adrenal hyperplasia (confirmed by genetic testing)
- Your doctor is switching you from regular hydrocortisone to modified-release hydrocortisone as part of your normal care
- Your steroid medications (both glucocorticoid and mineralocorticoid) have been stable before making this switch
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
- You do not take other medications that interfere with how your body processes steroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a once-daily hydrocortisone tablet works as well as standard steroid treatment for adults with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. It aims to improve how safely and conveniently hormone replacement is taken each day.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This study looks at the long-term experiences of adults with classic congenital adrenal hyperplasia (CAH), a condition affecting hormone production. It aims to understand patient satisfaction and health outcomes over time.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This study looks at fertility and sexual function in people with congenital adrenal hyperplasia (CAH), a condition affecting hormone production. It aims to understand how CAH impacts these areas.
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
Hear when a new CAH - Congenital Adrenal Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.